TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
132.04
+0.91 (0.69%)
At close: Aug 13, 2025, 4:00 PM
132.75
+0.71 (0.54%)
After-hours: Aug 13, 2025, 7:47 PM EDT
TransMedics Group Revenue
TransMedics Group had revenue of $157.37M in the quarter ending June 30, 2025, with 37.68% growth. This brings the company's revenue in the last twelve months to $531.29M, up 48.09% year-over-year. In the year 2024, TransMedics Group had annual revenue of $441.54M with 82.74% growth.
Revenue (ttm)
$531.29M
Revenue Growth
+48.09%
P/S Ratio
8.37
Revenue / Employee
$729,797
Employees
728
Market Cap
4.50B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
Dec 28, 2019 | Pro | Pro | Pro |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 30, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TMDX News
- 9 days ago - TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial - PRNewsWire
- 12 days ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 12 days ago - TransMedics: Continued Strength Suggests Further Upside - Seeking Alpha
- 14 days ago - TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - TransMedics Reports Second Quarter 2025 Financial Results - PRNewsWire
- 15 days ago - TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference - PRNewsWire
- 19 days ago - Why TransMedics Remains A Buy Into 2026 - Seeking Alpha
- 21 days ago - This Company Transports Donated Organs. Its Stock Has Had a Roller-Coaster Ride. - Barrons